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Objective: Avidin exhibits ideal characteristics for targeted intra-cartilage drug delivery: its small size
and optimal positive charge enable rapid penetration through full-thickness cartilage and electrostatic
binding interactions that give long half-lives in vivo. Here we conjugated Avidin with dexamethasone
(DEX) and tested the hypothesis that single-dose Avidin-delivered DEX can ameliorate catabolic effects in
cytokine-challenged cartilage relevant to post-traumatic OA.
Methods: Avidin was covalently conjugated with DEX using fast (ester) and slow, pH-sensitive release
(hydrazone) linkers. DEX release kinetics from these conjugates was characterized using 3H-DEX-Avidin
(scintillation counting). Cartilage explants treated with IL-1a were cultured with or without Avidin-DEX
conjugates and compared to soluble DEX. Sulfated-glycosaminoglycan (sGAG) loss and biosynthesis rates
were measured using DMMB assay and 35S-incorporation, respectively. Chondrocyte viability was
measured using ﬂuorescence staining.
Results: Ester linker released DEX from Avidin signiﬁcantly faster than hydrazone under physiological
buffer conditions. Single dose Avidin-DEX suppressed cytokine-induced sGAG loss over 3-weeks, rescued
IL-1a-induced cell death, and restored sGAG synthesis levels without causing cytotoxicity. The two
Avidin-DEX conjugates in 1:1 combination (fast:slow) had the most prominent bioactivity compared to
single dose soluble-DEX, which had a shorter-lived effect and thus needed continuous replenishment
throughout the culture period to ameliorate catabolic effects.
Conclusion: Intra-cartilage drug delivery remains inadequate as drugs rapidly clear from the joint,
requiring multiple injections or sustained release of high doses in synovial ﬂuid. A single dose of Avidin-
conjugated drug enables rapid uptake and sustained delivery inside cartilage at low intratissue doses,
and potentially can minimize unwanted drug exposure to other joint tissues.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) affects individual joints making intra-
articular (i.a.) therapy a desirable treatment option1,2, yet simple
i.a. injection remains inadequate because drugs are cleared from
the joint space rapidly via the lymphatics or vasculature3,4. CurrentA. J. Grodzinsky, MIT, Room
A. Tel: 1-617-253-4969; Fax:
ternational. Published by Elsevier Lresearch focuses on i.a. injection of drug-encapsulating micro or
nanoparticles for slow release of drugs into the synovial ﬂuid5e7.
However, this approach does not assure penetration of drugs or
drug carriers into the dense extracellular matrix (ECM) of cartilage
unless a very high drug concentration is used. Such penetration is
critical since the majority of chondrocytes and ECM targets reside
in the tissue's middle and deep zones. Thus, drug carriers intended
for i.a. application should facilitate rapid drug transport into
cartilage and remain boundwithin to achieve sustained intra-tissue
therapeutic levels before they are cleared from the joint space.
We previously showed that such challenges of drug delivery
into cartilage can be overcome by using cationic nanoparticles lesstd. All rights reserved.
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charged aggrecan inside cartilage offers distinctive advantages for
using electrostatic interactions that maximize intra-tissue trans-
port, uptake and binding of cationic drug carrying particles. We
used a highly basic protein, Avidin (pI 10.5, net charge þ20, 7 nm
diameter8), as an example of a drug carrier, and reported a six-fold
upward Donnan partitioning factor at the synovial ﬂuidecartilage
interface (Fig. 1). This resulted in a steep intra-tissue concentra-
tion gradient that signiﬁcantly enhanced Avidin's transport and
uptake within various tissues of rabbit9 and rat knee joints in-
vivo10. Non-speciﬁc electrostatic interactions are weak and
reversible and thus allow Avidin to penetrate deep into cartilage.
Stronger binding mechanisms can dramatically slow diffusion of
drugs or drug carriers and limit their penetration; in contrast,
Avidin exhibited weak-reversible binding with intratissue binding
sites, allowing diffusion through full thickness of cartilage, yet
having a long retention period due to high binding site density of
negatively charged proteoglycans. Importantly, Avidin demon-
strated similar results even after enzymatic removal of 40% GAG in
cartilage to mimic early changes of post-traumatic osteoarthritis
(PTOA)8.
Traumatic joint injury, which progresses to PTOA with high
incidence rate11, is characterized by transiently increased synovial
ﬂuid concentrations of pro-inﬂammatory cytokines (e.g., IL-1, IL-6
and TNFa) that are associated with cartilage ECM proteolysis12e14.
Potential therapeutics, including anti-catabolic glucocorticoids
(e.g., dexamethasone (DEX), triamcinolone) and pro-anabolic
growth factors (e.g., IGF-1, FGF-18, BMP-7) are known to amelio-
rate cytokine-induced cartilage degradation in vitro15e18. DEX has
been shown to suppress cytokine-induced ECM catabolism via GC
receptor-dependent pathways16, and, together with anabolic fac-
tors (e.g., IGF-1) can maintain matrix biosynthesis levels18. How-
ever, in animal19e21 and human studies22, ineffective intratissue
delivery necessitates high i.a. drug doses which, for glucocorticoids,Fig. 1. Schematic of the concept underlying the drug delivery scheme developed. (A) Avidin
thickness of cartilage owing to weak and reversible electrostatic binding with the negativ
enables rapid transport into and within the cartilage8. (C) A single dose of Avidin-conjugated
chondrocytes which suppressed cytokine-induced loss of sGAG and chondrocyte viability. Scan cause bone resorption and systemic organ toxicity. Thus, an
effective treatment to prevent cartilage degradation associated
with PTOAwould beneﬁt from delivery of sustained low drug doses
inside cartilage.
The objectives of this study were to (1) devise a method to
conjugate DEX to Avidin and quantify the release of DEX from
Avidin-DEX complexes, and (2) test the ability of a single initial
dose of Avidin-DEX to inhibit cytokine-induced ECM degrada-
tion, rescue cell biosynthesis rates and loss of cell viability in
cartilage explants over long durations after penetration/binding
of Avidin-DEX into cartilage (depicted schematically in Fig. 1). A
combination of fast and slow release chemical linkers for
conjugation is used to enable sustained release of DEX inside
cartilage. We found that a single dose of Avidin-DEX inhibited
cytokine-induced explant catabolism over 3-weeks, while a sin-
gle dose of soluble DEX had short-lived efﬁcacy and thus
required continuous replenishment. Avidin-DEX also inhibited
cytokine-induced loss of chondrocyte viability and rescued ma-
trix biosynthesis levels. Avidin has been reported to have no
adverse effects on safety in humans23,24 and no effects on
cartilage viability or biosynthesis even at high concentrations in-
vitro10. Nevertheless, as covalent attachment of poly(ethylene
glycol) (PEG) can further shield potential immunogenic re-
sponses25 to highly cationic species, we conjugated PEG to Avidin
to further ensure in vivo compatibility.
Materials and methods
The chemical structures and schematics of the four conﬁgura-
tions of Avidin-DEX conjugates synthesized for this study are
shown in Fig. 2. Initially, DEX was supramolecularly encapsulated
within native (Fig. 2A) and PEGylated (Fig. 2B) Avidin to construct a
nanoscale, Avidin-based drug delivery vehicle (abbreviated as
Avþ DEX and PEG-Avþ DEX, respectively). In addition, to achievenanoparticles due to their ideal size and high positive charge can penetrate through full
ely charged aggrecan within cartilage. (B) A high upward Donnan partitioning factor
DEX using fast (ester) and slow release linkers (hydrazone) enabled delivery of DEX to
Z ¼ superﬁcial zone of cartilage, DZ ¼ deep zone.
Fig. 2. Schematic representation and chemical structures of the four Avidin (Av) conjugated DEX compounds formulated. (A) Av þ DEX: Avidin supramolecularly (non-covalently)
loaded with DEX. (B) PEG-Av þ DEX: PEGylated Avidin supramolecularly (non-covalently) loaded with DEX. (C) Fast release PEG-Av-ester-DEX: PEGylated Avidin covalently
conjugated with DEX using ester linkers. (D) Slow release PEG-Av-hydrazone-DEX: PEGylated Avidin covalently conjugated with DEX using pH sensitive hydrazone (HZ) linkers.
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construct, we attached DEX to biotinylated PEG through ester (for
fast drug release (Fig. 2C)) or hydrazone (for slower and sustained
release (Fig. 2D)) linkages, which in turn were supramolecularly
coupled to Avidin through the Avidin-biotin interaction. Drug
release proﬁles from these two covalently modiﬁed constructs
(PEG-Av-ester-DEX and PEG-Av-hydrazone-DEX) were compared
with their non-covalently constructed counterparts (Fig. 2A,B). The
biological activity of these constructs was then tested using anin vitro model of cartilage catabolic injury incorporating IL-1a-
treated cartilage explants in organ culture.
Supramolecular entrapment of Avidin with 3H-DEX (non-covalent
conjugation)
All chemical compounds were purchased from Sigma Aldrich,
MO unless speciﬁed. Compound A (Av þ DEX, Fig. 2A) was syn-
thesized by dissolving Avidin in 1  PBS and adding to the solution
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Avidin used, and an amount of 3H-DEX (speciﬁc radioactivity:
100 Ci/mmol, concentration: 1 mCi/mL, American Radiolabeled
Chemicals, MO) equivalent to a ﬁnal concentration of 5 mCi/mL.
For synthesizing compound B (PEG-Av þ DEX, Fig. 2B), Avidin
was PEGylated utilizing its 4 biotin binding sites by mixing 4 molar
equivalents of biotinylated PEG-amine (2.3 kDa) with 1 molar
equivalent of Avidin (Invitrogen, CA) in 1  PBS at room tempera-
ture for 2.5 h. The ﬂuorescent probe 2,6-ANS (Invitrogen, CA) dye
assay was used to conﬁrm stoichiometric binding of biotinylated
PEG to Avidin as described26. Conjugation of biotinylated PEG to
Avidin affects its relative electrophoretic mobility27; this was
conﬁrmed using SDS-PAGE in 4e12% separating gels (NuPAGE
Novex 4e12% Bis-Tris gel System, Life Technologies, CA) under
reducing conditions. The gels were then stained for protein (Coo-
massie brilliant blue). Similar to compound A, we added an amount
of unlabeled DEX equivalent to two-times the weight of Avidin
used, and enough 3H-DEX to yield a ﬁnal concentration of 5 mCi/mL.
The solutions (both PEGylated and native Avidin) were stirred
overnight at room temperature, ﬁltered (0.2 mmmesh), then ultra-
ﬁltered (3.5 kDa mesh, spinning at 8,000 g for 30 min) to remove
free DEX from the solution that was not functionalized to Avidin.
The ﬁnal DEX concentration was estimated by measuring radioac-
tivity (microBeta TriLux liquid scintillation counter, Perkin Elmer).
Avidin concentration was determined using the bicinchoninic acid
(BCA) assay28. Drug loading content (DLC) of the ﬁnal solutions was
estimated by:
DLC ¼ Total drug encapsulatedðgÞ
Total drug encapsulatedðgÞ þMass of AvidinðgÞ  100%
Synthesis of compounds C (PEG-Av-ester-DEX) and D (PEG-Av-
hydrazone-DEX)
Compounds C and D (Fig. 2) were synthesized by two-step re-
action protocols. In the ﬁrst step, DEX was conjugated to bio-
tinylated PEG through either an ester (3, Scheme-1, Supplementary
material) or a pH sensitive hydrazone linker (6, Scheme-2,
Supplementary material). In the second step, biotinylated PEG-
DEX conjugate was supramolecularly attached to Avidin. (Synthe-
sis steps for both ester and hydrazone linkers are described in
Schemes-1 and -2 of Supplementary material).
In-vitro drug release
Release of DEX from Avidin-conjugated DEX compounds was
measured using dialysis membranes (Spectra/Por Float-A-Lyzer G2)
having molecular weight cutoff 3,500 Da. A solution of Avidin-
conjugated 3H-DEX (5 mL) was placed in a dialysis bag immersed
in a ﬂask containing 200mL of 1 PBS at pH 7.4 or 4.0 (the latter for
hydrazone-linked conjugate; pH adjusted with 1.0N HCl) at 37C,
with continuous magnetic stirring. At different time intervals
(starting at t¼ 0), aliquots of solution (50 mL) werewithdrawn from
inside the dialysis bag and the radioactivity measured (liquid
scintillation) to estimate the concentration of residual 3H-DEX-
Avidin in the dialysis bag. The percent 3H-DEX release was calcu-
lated using as follows, where t is the time at which radioactivity is
measured and to is the initial time:
%Drug Released ¼

1 radioactivityðtÞ
radioactivityðtoÞ

 100%Biological response of cartilage in vitro
Cartilage disks (3 mm diam, 1 mm thick) with intact superﬁcial
zone were harvested from femoropatellar grooves of 1e2 week old
bovine calf knees (Research 87, Hopkinton, MA) as described8.
Cartilage disks for all treatment groupswerematched for depth and
location along the joint surface. Disks were equilibrated in serum-
free medium (low-glucose DMEM (Cellgro, VA)), 10 mM HEPES
buffer (Invitrogen, CA), supplemented with 1% ITS (insulin-trans-
ferrin-selenium, 10 mg/ml, 5.5 mg/ml and 5 ng/ml, respectively),
0.1 mM nonessential amino acids, 0.4 mM proline, 20 mg/mL
ascorbic acid, 100 units/mL penicillin G, 100 mg/mL streptomycin,
and 0.25 mg/mL amphotericin B for 2 days in a 37C, 5% CO2 incu-
bator prior to treatment.Treatment of cartilage with exogenous cytokine and soluble DEX
To establish the baseline comparison for studying the effec-
tiveness of Avidin-DEX constructs, we ﬁrst treated groups of
cartilage explants with IL-1a (1 ng/mL) for 16 days in the presence
of the following DEX-treatment conditions: (1) single initial dose of
100 nM soluble DEX, and (2) continuous dose of 100 nM DEX.
Medium was changed every 2 days and IL-1a was replenished at
each medium change. In the ‘single DEX dose’ condition, cartilage
explants were subjected to DEX for only the ﬁrst 2 days, and sub-
sequent medium changes did not contain DEX, thereby simulating
a single i.a. injection of DEX in vivo. Medium for the ‘continuous
DEX dose’ treatments was, however, replenished with DEX
throughout the duration of the 16-day culture.Treatment with Avidin covalently-conjugated DEX compounds
To determine the concentration of Avidin-conjugated DEX that
would effectively suppress IL-1a-induced GAG loss in cartilage
with only one dose added on day-0 of culture, cartilage explants
were treated with or without IL-1a (1 ng/mL) and incubated for
8 days with one dose of increasing concentrations of PEG-Av-
ester-DEX compound (DEX concentrations of 100 nM, 4 mM and
100 mM). Since 4 mol of DEX are covalently conjugated with 1 mol
of Avidin using ester linker, these DEX concentrations imply
Avidin loading of 25 nM, 1 mM and 25 mM respectively. To test the
biological effectiveness of Avidin-conjugated DEX compounds, we
treated cartilage explants with or without IL-1a (1 ng/mL) for 8, 16
or 22 days in combination with: (1) one-time dose of Avidin-
conjugated DEX using ester linker (PEG-Av-ester-DEX, com-
pound C), (2) one time dose of Avidin-conjugated DEX using
hydrazone linker (PEG-Av-hydrazone-DEX, compound D), (3) one
time dose of a 1:1 M ratio of compounds C and D, (4) one time
dose of soluble DEX. An effective concentration of 100 mM DEX
was used in all treatments.Chondrocyte viability in explant culture with Avidin-DEX
compounds
Upon termination of culture, 100e200 mm thick slices were cut
from the center of disks from each treatment condition using
establishedmethods8. Slices were immediately stained for 2e3min
in the dark with Fluorescein Diacetate (FDA; 4 mg/ml in PBS) and
Propidium Iodide (PI; 40 mg/ml in PBS). FDA stained viable cells
green and PI stained non-viable cells red10. Slices were washed
with PBS and imaged (Nikon ﬂuorescence microscope; 4
objective).
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Two days before termination of 8-day cartilage cultures, the
medium was supplemented with 5 mCi/mL [35S]-sulfate (Perki-
nElmer, CT). After 2-day radiolabel period, explants were washed 4
times over 80 min with cold PBS to remove free label. Each indi-
vidual explant was ﬁrst weighed wet and then digested with
proteinase-K (Roche, MN) overnight. Cumulative release of sGAG to
the medium and residual sGAG in the digested explants were
measured using the dimethyl-methylene blue (DMMB) dye binding
assay29. Radiolabel in each digested sample and medium standards
(35S) were measured (liquid scintillation); radiolabel concentration
was calculated from the standards and normalized to explant wet
weight.
Statistical analysis
For all cartilage explant studies, we used the general linear
mixed effects model with animal as a random variable, followed by
Tukey's Honestly Signiﬁcant Difference test for comparisons be-
tweenmultiple treatment conditions. There was no effect of animal
found and, hence, data across animals were pooled. P-values less
than 0.05 were considered statistically signiﬁcant.
Results
Characterization of Avidin-conjugated DEX compounds
As shown in Fig. 2 the following chemical compounds of Avidin
loaded DEX were prepared: (A) Av þ DEX, (B) PEG-Av þ DEX, (C)
PEG-Av-ester-DEX and (D) PEG-Av-hydrazone-DEX. Their drug
loading content values (DLC, mean ± SD) are reported in Table I.
Compounds C and D have 4 mol of DEX covalently bound with
1 mol of Avidin using ester or hydrazone linker; thus, based on
molar masses, a theoretical DLC value of 2.3% is expected for fully
conjugated Avidin. The molar ratio of biotinylated PEG to Avidin in
compounds BeDwas determined by the ﬂuorescent probe 2,6-ANS
dye assay. Addition of biotinylated PEG to the 2,6-ANS dye and
Avidin solution displaced the ANS dye, resulting in reduction of
ﬂuorescence intensity with increasing molar ratio of biotinylated
PEG to Avidin (Fig. 3A). A plateau in ﬂuorescence value was ach-
ieved starting at 4:1 M ratio of biotinylated PEG to Avidin, as ex-
pected. Conjugation of Avidinwith biotinylated PEG also resulted in
a shift of molecular weight as observed in SDS-PAGE from the band
at ~16 kDa (Fig. 3B, monomeric form of Avidin (Av lane) shifted to
the broader band at higher MW (PEG-Av lane) due to addition of
2.3 kDa PEG chains).
In-vitro DEX release from Avidin
Release proﬁles of 3H-DEX from non-covalent compounds in
PBS at 37C and pH 7.4 are shown in Fig. 4A. ~70% of loaded DEX
was released from compound A (Av þ DEX) in 3 h. PEGylation of
Avidin (Compound B) did not alter this release rate which was
similar to DEX diffusivity in PBS, suggesting absence of any robustTable I
DLC (Mean ± SD) for Avidin conjugated DEX compounds
Compound Compound type DLC (wt%)
A Av þ DEX 33.2 ± 4.8
B PEG-Av þ DEX 32.8 ± 3.6
C PEG-Av-ester-DEX 2.2 ± 0.3
D PEG-Av-hydrazone-DEX 1.9 ± 0.1binding interaction between DEX and the macromolecular as-
sembly of Avidin or PEGylated-Avidin. In contrast, conjugation of
DEX to Avidin via ester linkage dramatically slowed the release of
DEX (Fig. 4B, compound C), resulting in a half-life of 14.4 ± 1 h at
pH 7.4 (mean life time ¼ 20.8 h). This half-life was calculated by
ﬁtting a ﬁrst order exponential decay curve to the measured
average concentration inside the dialysis membrane vs time (inset
of Fig. 4B).
Conjugation of DEX to Avidin via hydrazone linkage (com-
pound D) slowed DEX release even further (Fig. 4C). The hydra-
zone bond underwent only limited cleavage at pH 7.4, with
maximum release at 30% loading. This bond, however, becomes
less stable in an acidic environment30e32. Consistent with this
behavior, DEX release from hydrazone linker at pH 4 showed a
mean half-life of 57.4 ± 3.6 h. The initial fast release of DEXmay be
attributed to non-covalently bound DEX on Avidin, implying a
longer half-life than 57.4 h.Avidin-DEX compounds did not affect chondrocyte viability in
cartilage explants
The cytotoxicity of Avidin-DEX compounds was evaluated by
assessing chondrocyte viability in cartilage explants using the live-
dead ﬂuorescence assay. Cartilage explants were treated for 48 h
with compounds C and D, PEG-Av-ester-DEX and PEG-Av-
hydrazone-DEX (ﬁnal DEX concentration of 100 mM). Representa-
tive images from 3 to 4 cartilage disks from all treatment conditions
at 48 h (Fig. 5B,C) showed minimal cell death and were similar to
untreated controls (Fig. 5A). (Some cell death in the superﬁcial zone
was typically observed in untreated control explants, depending on
the location of harvesting along the joint).Effect of single vs continuous dose of soluble DEX on IL-1a treated
cartilage
As expected, IL-1a treatment caused increased loss of sGAG-
containing aggrecan fragments from cartilage explants over 16
days compared to controls (Fig. 6, P < 0.0001 all time points). Cu-
mulative sGAG loss was 5e6 higher in IL-1a treated explants
compared to untreated controls by day-16. Both single dose (day-
0e2) and continuous doses (starting day-0) of 100 nM DEX
inhibited sGAG loss until day-10 compared to IL-1a alone
(P < 0.0001). However, at day-12, there was a substantial increase
in sGAG loss from the single DEX dose explant condition
(P < 0.0001), at the same rate as that from IL-1a treatment alone,
while the continuous DEX dose maintained inhibition of sGAG loss
at the same rate through day-16.Dose dependent bioactivity of Avidin-DEX compounds in cartilage
As shown in Fig. 6, a low but continuous dose of 100 nM DEX
was sufﬁcient in suppressing IL-1a-induced GAG loss from
cartilage explants. To determine the concentration of DEX from
one dose of Avidin-delivered DEX that would effectively suppress
GAG loss for long times, we tested the dose-dependent response
of PEG-Avidin-ester-DEX (compound C) on IL-1-treated explants
over 8-days (Fig. 7A). We found that one dose of all DEX con-
centrations (100 nme100 mM) in compound C could suppress IL-
1-induced GAG loss; however, the effect was most prominent
using the 100 mM DEX-equivalent concentration (Fig. 7A). Hence,
a concentration of 100 mM DEX delivered through Avidin con-
jugated DEX structures was chosen for subsequent experiments.
Fig. 3. (A) Titration curve of 2,6 ANS-ﬂuorometric assay for stoichiometry of biotin-PEG (2,300 Da) with Avidin in PBS buffer at pH 7.4. (B) SDS PAGE (4e12%) of Avidin (Av) and
PEGylated Avidin (PEG Av) under reducing conditions stained with Coomassie Blue.
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IL-1a
Figure 7B compares cumulative IL-1-induced GAG loss over 22-
days in the presence of a single dose of 100 mM soluble DEX vs aFig. 4. (A) In vitro 3H-DEX release proﬁles for non-covalently DEX loaded Avidin compounds
37C. (B) In vitro 3H-DEX release proﬁle for PEG-Av-ester-DEX in PBS (pH 7.4) at 37C. Ester, a
is the DEX concentration at time t, A0 is the initial DEX concentration inside the dialysis mem
calculated as t1=2 ¼ lnð2Þl . (C) 3H-DEX release proﬁles for PEG-Av-hydrazone-DEX in PBS at 37
hence resulted in a slow release of DEX in acidic environment (pH 4) with a mean half-life o
conﬁdence interval.single dose of 100 mM DEX delivered via Avidin (using ester and
hydrazone linkers, compounds C and D). IL-1a treatment increased
GAG loss compared to untreated controls at all time points (Fig. 7B,
P < 0.0001). When IL-1a-treated explants were incubated with a
single dose of soluble DEX from day 0e2, GAG loss was markedlycompared with diffusivity of 3H-DEX through the dialysis membrane in PBS (pH 7.4) at
fast release linker, resulted in a mean half-life of 14.4 h. AðtÞ ¼ A0expðltÞ, where AðtÞ
brane at t ¼ 0 and 1=l is the characteristic exponential decay time. The half-life ðt1=2Þ is
C at pH 7.4 (diamonds) and at pH 4 (squares). Hydrazone is an acid cleavable linker, and
f 57.4 h. Data is from 4 to 5 DEX release experiments and are presented as Mean ± 95%
Fig. 5. Images of ﬂuorescently stained bovine cartilage explants to check for chondrocyte viability after 48 h incubation with (A) basal media, untreated control (B) PEG Av-ester-
DEX and (C) PEG Av-hydrazone-DEX. Effective DEX concentration of 100 mM was used. Green indicates viable cells and red indicates non-viable cells.
Fig. 6. Effect of one dose vs continuous dose of 100 nM DEX on IL-1a simulated GAG
loss in bovine cartilage explants. Cartilage tissues were cultured with or without IL-1a
(1 ng/mL) and with one time dose of 100 nM DEX or continuous dose of 100 nM DEX
for 16 days. Data are presented as Mean ± 95% conﬁdence intervals, N ¼ 3 animals,
n ¼ 6 explants for each treatment condition from each animal (18 explants per con-
dition). All treatment conditions are signiﬁcantly different from the untreated control.
Error bars for the untreated control data points are small and thus not visible. * vs IL-1a
alone, # vs one dose DEX, $ vs continuous dose DEX, P < 0.0001.
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with a single dose of compound C (PEG-Av-ester-DEX) suppressed
GAG loss even further than soluble DEX alone (P < 0.0001
compared to soluble DEX, all time points). PEG-Av-hydrazone-DEX
inhibited sGAG loss in a manner similar to soluble DEX at earlier
time points. While soluble DEX appeared to lose its effect by day 18,
PEG-Av-hydrazone-DEX showed more effective inhibition of sGAG
loss by days-20 to 22 (P¼ 0.038 compared to single dose DEX at day
22). Finally, a 1:1 M ratio of two linker chemistries with effective
DEX concentration of 100 mM performed better than the slow-
releasing hydrazone linker (P ¼ 0.001 at day-2, P < 0.0001, subse-
quent time points) but similarly to ester linker (Fig. 7B).
Avidin-DEX rescued biosynthesis rates and chondrocyte viability in
IL-1a-treated cartilage
Compared to untreated controls, sulfate incorporation was
greatly suppressed by IL-1a-treatment in bovine cartilage explants
by day 8 of culture (Fig. 8A, P < 0.0001). Addition of a single dose of
100 mM soluble DEX from day 0e2 or continuous dose of soluble
100 nM DEX increased 35S-sulfate incorporation compared to IL-1 a
alone (P < 0.0001). One dose of PEG-Av-ester-DEX and PEG-Av-
hydrazone-DEX also had similar rescuing effects. In addition,
Avidin-conjugated DEX rescued chondrocyte viability in the pres-
ence of IL-1a (Fig. 8B ievi). A dramatic increase in cell death wasobserved after treatment with IL-1 alone by day-8 (Fig. 8B ii). In
contrast, addition of a single dose of 100 mM DEX on day 0e2
(Fig. 8B iii) or a continuous dose of 100 nM DEX (Fig. 8B iv) suc-
cessfully prevented cell death induced by IL-1a. Treatment with a
single dose of PEG-Av-ester-DEX or PEG-Av-hydrazone-DEX
(Fig. 8B vevi) added on day 0e2, also successfully rescued chon-
drocyte death similar to that observed using the soluble DEX
conditions.
Discussion
This work demonstrates a drug delivery approach to long term
suppression of cytokine-induced loss of GAG and chondrocyte
viability inside cartilage with just a single-dose treatment exem-
pliﬁed using Avidin-conjugated DEX. Avidin, due to its ideal size
and positive charge, rapidly penetrates through full thickness
cartilage due to electrostatic interactions and reversible binding
within tissue, resulting in long half-lives in-vivo9,10. We used a
combination of fast (ester) and slow release-pH cleavable (hydra-
zone) linkers to conjugate DEX with Avidin and compared its bio-
logical efﬁcacy with a single dose of soluble DEX in an IL-1a-
challenged cartilage explant model. IL-1a is one of the family of
inﬂammatory cytokines that is thought to play a critical role in the
initial events associated with progression to PTOA14 and causes
GAG loss by up-regulating ADAMTS-4,5 in bovine33 as well as hu-
man14 cartilage. We used DEX as an example drug as it has been
previously shown to block cytokine-induced cartilage
degradation16,18.
Our data show that a single dose of DEX alone could not provide
long term suppression of GAG loss compared to continuous DEX
treatment during culture. Removal of 100 nM DEX after day 0e2
provided inhibition of GAG loss only for the ﬁrst 8 days (Fig. 6), after
which increased aggrecan catabolism continued, such that the cu-
mulative GAG loss by day 16 was 1.8 higher than the continuous
DEX dose condition. However only a single dose of either PEG-Av-
ester-DEX or compound Cþ D (1:1 M ratio of ester and hydrazone)
added at day 0e2 was needed to signiﬁcantly reduce IL-1-induced
GAG loss compared to the soluble DEX condition over 3-weeks
(Fig. 7B). Compound D had a similar effect as 1-dose soluble DEX
at earlier time points, but by day-22, a signiﬁcantly greater sup-
pression of GAG loss was observed. In separate experiments, there
was negligible uptake of Avidin by the chondrocytes (Fig. S1
Supplementary material). Thus, we conjugated DEX to Avidin us-
ing hydrolysable linkers like ester and hydrazone to facilitate
release of DEX, making it available for uptake by chondrocytes.
The ester (compound C) is a fast-releasing linker giving a mean
half-life of 14.4 h at physiological conditions (Fig. 4B), suggesting
that 70% of the loaded DEX released before the ﬁrst medium change
(48 h after start of culture), thereby providing an initial appropriate
Fig. 7. (A) Effect of one dose of compound C (PEG-Av-ester DEX) on cumulative sGAG loss in IL-1a (1 ng/ml) treated bovine cartilage explants at day 8 of culture period. Effective
DEX concentration in these compounds is shown in brackets (100 nMe100 mM). Data are presented as Mean ± 95% conﬁdence interval, N ¼ 2 animals, n ¼ 6e8 explants each
treatment condition. * vs IL-1a alone, # vs 100 mMDEX, P < 0.0001. (B) Effect of one dose of effective DEX concentration of 100 mM in cumulative sGAG loss in IL-1a (1 ng/ml) treated
bovine cartilage explants over a period of 22 days. One dose of DEX was provided in form of soluble DEX (green), compound C (PEG-Av-ester DEX, purple), compound D (PEG-Av-
hydrazone DEX, blue) or 1:1 M ratio of compounds C and D (yellow). Black line shows cumulative sGAG loss in untreated control cartilage and the red line shows the sGAG loss in IL-
1a alone treated cartilage over a period of 22 days. Values are Mean ± 95% conﬁdence interval, N ¼ 4 animals, n ¼ 6e12 explants each condition from each animal. All conditions are
signiﬁcantly different from IL-1 alone (red) at all time points (P < 0.0001). Soluble DEX (green) and compound D (blue) are signiﬁcantly different from control (black) starting at day
4 (P < 0.0001). Compound C (purple) and the combination C þ D (yellow) are signiﬁcantly different from control (black) starting at day 10 (P < 0.0001) and day 8 (P ¼ 0.001 at day 8
and P < 0.0001 starting day 10) respectively.
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iting IL-1a-induced catabolic effects. Hydrazone is a slow releasing
linker with a mean half-life of 57.4 h at low pH4 (Fig. 4C). As it
cleaves in acidic environments34, hydrazone should release DEX
closer to negatively charged GAG chains in the chondrocyte peri-
cellular matrix (where aggrecan concentration is highest35). Addi-
tionally, a decrease in pH from 7.4 to 5.5 was reported at cartilage
surfaces of OA patients4. At the micro-scale aggrecan density in-
creases with depth into cartilage from the superﬁcial zone36. Thus,
as Avidin carries the drug into middle-deep zones of cartilage
where most chondrocytes reside, the rate of drug release from
hydrazone linker should increase with depth into cartilage. A
combination of ester and hydrazone is expected to yield greater
rescuing effect at longer times in-vivo, and this approach iscurrently being tested in a rabbit anterior cruciate ligament tran-
section (ACLT) model of PTOA.
Treatment with Avidin-DEX compounds did not cause cytotoxic
effects as there was no effect on chondrocyte viability (Fig. 5). Both
compounds rescued cytokine-induced decrease in biosynthesis and
chondrocyte viability, similar to soluble DEX conditions (Fig. 8A, B).
Previously, we showed that Avidin alone, up to 100 mM concen-
tration, did not affect chondrocyte biosynthesis of proteins and
proteoglycans in similar-aged bovine cartilage explants10. Here, we
used one dose of <25 mM Avidin for delivering 100 mM DEX to
cartilage explants in low glucose medium containing 1% ITS.
Therapeutic use of Avidin can elicit the production of anti-Avidin
antibodies in-vivo23,37,38 but this has been shown to have no ef-
fect on its safety or efﬁcacy in humans23,39.
Fig. 8. (A) Rate of sGAG synthesis during the last 48 h of the 8 days culture time period normalized by the wet weight of cartilage explants. Data are presented as Mean ± 95%
conﬁdence interval. N ¼ 4 animals, n ¼ 6 explants each condition from each animal. * vs IL-1a alone, P < 0.0001. One dose of compounds C, D and DEX (effective DEX concentration
of 100 mM) are compared to continuous dose of 100 nm DEX. (B) Images of ﬂuorescently stained bovine cartilage explants (4 objective) cultured for 8 days to check for chondrocyte
viability in (i) basal medium, untreated control (ii) treated with 1 ng/ml of IL-1a alone. The following conditions were treated with IL-1a (1 ng/ml) along with (iii) one dose of
100 mM soluble DEX (iv) continuous dose of 100 nM soluble DEX during 8 days of culture (v) one dose of PEG-Av-ester-DEX and (vi) one dose of PEG-Av-hydrazone (HZ)-DEX (ﬁnal
DEX concentration of 100 mM in (v) and (vi)). Green indicates viable cells and red indicates non-viable cells. The top edge of each image (arrow) shows the superﬁcial zone and the
bottom represents the transected middle/deep zone. Scale bar ¼ 200 mm.
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using culture medium without synovial ﬂuid (SF). Hyaluronic acid
and other negatively charged moieties in SF could in principle lead
to binding of Avidin, preventing penetration of Avidin and conju-
gated drugs into cartilage. However, as we reported previously, i.a.
injection of Avidin into rabbit9 and rat10 knee joints in vivo resulted
in Avidin penetration from knee SF into the superﬁcial zone and
through the full thickness of joint cartilages, as documented by
confocal images10 and by direct measurement of the half-lives of
Avidin inside these knee cartilages9,10. Additionally, in separate
tests, we observed that the release of DEX from PEG-Av-ester-DEX
and PEG-Av-hydrazone-DEX after 100 h in bovine SF in vitro is
similar to that found in the PBS conditions of the present manu-
script. We therefore suggest that Avidin-DEX compounds canindeed be carried into cartilage in vivo, and are currently testing
this approach in a rabbit ACLT model.
In summary, Avidin as a nano-carrier can rapidly transport
candidate DMOADs into the middle and deep zones of cartilage and
bind reversibly inside the tissue, thereby creating a drug reservoir
and providing sustained delivery to nearby cell and ECM targets. It
is now accepted that multiple DMOADs may be useful for disease
modiﬁcation15. One example of such a drug combination would be
a pro-anabolic growth factor (e.g., IGF-117,40) known to stimulate
cartilage repair, and an anti-catabolic glucocorticoid (e.g., DEX18).
Growth factors such as IGF-1 can be similarly conjugated with
Avidin by using a combination of slow and fast drug releasing
chemical linkers to enable targeted and sustained delivery inside
cartilage along with glucocorticoids.
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